{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2013:HHV2DJIGUCFFG3P2GSZ22WPTSF","short_pith_number":"pith:HHV2DJIG","canonical_record":{"source":{"id":"1303.2803","kind":"arxiv","version":2},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2013-03-12T08:31:19Z","cross_cats_sorted":[],"title_canon_sha256":"08faf0cb8263c47f89b83136986af4e8d0cd1dc6d779942a6831bb7f98664cc0","abstract_canon_sha256":"39ddcdb62139a31a8800153cb724186afd8c685b63d4d8f47a53c1d0e2087897"},"schema_version":"1.0"},"canonical_sha256":"39eba1a506a08a536dfa34b3ad59f39157bf71264a9b7232c84cb5f32209a646","source":{"kind":"arxiv","id":"1303.2803","version":2},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1303.2803","created_at":"2026-05-18T02:56:12Z"},{"alias_kind":"arxiv_version","alias_value":"1303.2803v2","created_at":"2026-05-18T02:56:12Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1303.2803","created_at":"2026-05-18T02:56:12Z"},{"alias_kind":"pith_short_12","alias_value":"HHV2DJIGUCFF","created_at":"2026-05-18T12:27:46Z"},{"alias_kind":"pith_short_16","alias_value":"HHV2DJIGUCFFG3P2","created_at":"2026-05-18T12:27:46Z"},{"alias_kind":"pith_short_8","alias_value":"HHV2DJIG","created_at":"2026-05-18T12:27:46Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2013:HHV2DJIGUCFFG3P2GSZ22WPTSF","target":"record","payload":{"canonical_record":{"source":{"id":"1303.2803","kind":"arxiv","version":2},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2013-03-12T08:31:19Z","cross_cats_sorted":[],"title_canon_sha256":"08faf0cb8263c47f89b83136986af4e8d0cd1dc6d779942a6831bb7f98664cc0","abstract_canon_sha256":"39ddcdb62139a31a8800153cb724186afd8c685b63d4d8f47a53c1d0e2087897"},"schema_version":"1.0"},"canonical_sha256":"39eba1a506a08a536dfa34b3ad59f39157bf71264a9b7232c84cb5f32209a646","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-18T02:56:12.769094Z","signature_b64":"FnFZnJy4AsuXcHi0zYbLdGzT8T3MIU1iKsCbAzQUOhMegj9WbnOi9es/mdwggYYsTBYT0g/yDLFPJKHoMLpxDA==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"39eba1a506a08a536dfa34b3ad59f39157bf71264a9b7232c84cb5f32209a646","last_reissued_at":"2026-05-18T02:56:12.768733Z","signature_status":"signed_v1","first_computed_at":"2026-05-18T02:56:12.768733Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"1303.2803","source_version":2,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T02:56:12Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"k7Gu3PO1Uj2x3Ayuj3IgrwdVFrvd0SyXHwnUnllL6DCYIXJwVqqozc3jd/S/BictDZY9pPy8q21RNsrR6YvlAg==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-05-25T11:59:04.373697Z"},"content_sha256":"29c3b1da096e646fe93c2dd30aad4a58e9a947bef216ece16b8d9b7d8994edcf","schema_version":"1.0","event_id":"sha256:29c3b1da096e646fe93c2dd30aad4a58e9a947bef216ece16b8d9b7d8994edcf"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2013:HHV2DJIGUCFFG3P2GSZ22WPTSF","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: systematic review and meta-regression","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":[],"primary_cat":"stat.AP","authors_text":"Christian R\\\"over, Richard Nicholas, Sebastian Straube, Simon M. Steinvorth, Simon Schneider, Tim Friede","submitted_at":"2013-03-12T08:31:19Z","abstract_excerpt":"Background: Recent studies have shown a decrease in annualised relapse rates (ARRs) in placebo groups of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RMS).\n  Methods: We conducted a systematic literature search of RCTs in RMS. Data on eligibility criteria and baseline characteristics were extracted and tested for significant trends over time. A meta-regression was conducted to estimate their contribution to the decrease of trial ARRs over time.\n  Results: We identified 56 studies. Patient age at baseline (p < 0.001), mean duration of multiple sclerosis (MS) at baseline "},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1303.2803","kind":"arxiv","version":2},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T02:56:12Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"6y9HjshVtKx6jqvm7KpCF7Tr/B4Masr3Al5NmPJUC14rwd53JHdrN3RvaQ4LOqMrIwXKuR6xqaYa+fg17TEBAA==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-05-25T11:59:04.374389Z"},"content_sha256":"11ac6f2a5cfe9ad3f5fcfdb9c45443f3a839ecf4015134c5d31ed3e33b2db529","schema_version":"1.0","event_id":"sha256:11ac6f2a5cfe9ad3f5fcfdb9c45443f3a839ecf4015134c5d31ed3e33b2db529"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/HHV2DJIGUCFFG3P2GSZ22WPTSF/bundle.json","state_url":"https://pith.science/pith/HHV2DJIGUCFFG3P2GSZ22WPTSF/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/HHV2DJIGUCFFG3P2GSZ22WPTSF/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-05-25T11:59:04Z","links":{"resolver":"https://pith.science/pith/HHV2DJIGUCFFG3P2GSZ22WPTSF","bundle":"https://pith.science/pith/HHV2DJIGUCFFG3P2GSZ22WPTSF/bundle.json","state":"https://pith.science/pith/HHV2DJIGUCFFG3P2GSZ22WPTSF/state.json","well_known_bundle":"https://pith.science/.well-known/pith/HHV2DJIGUCFFG3P2GSZ22WPTSF/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2013:HHV2DJIGUCFFG3P2GSZ22WPTSF","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"39ddcdb62139a31a8800153cb724186afd8c685b63d4d8f47a53c1d0e2087897","cross_cats_sorted":[],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2013-03-12T08:31:19Z","title_canon_sha256":"08faf0cb8263c47f89b83136986af4e8d0cd1dc6d779942a6831bb7f98664cc0"},"schema_version":"1.0","source":{"id":"1303.2803","kind":"arxiv","version":2}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1303.2803","created_at":"2026-05-18T02:56:12Z"},{"alias_kind":"arxiv_version","alias_value":"1303.2803v2","created_at":"2026-05-18T02:56:12Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1303.2803","created_at":"2026-05-18T02:56:12Z"},{"alias_kind":"pith_short_12","alias_value":"HHV2DJIGUCFF","created_at":"2026-05-18T12:27:46Z"},{"alias_kind":"pith_short_16","alias_value":"HHV2DJIGUCFFG3P2","created_at":"2026-05-18T12:27:46Z"},{"alias_kind":"pith_short_8","alias_value":"HHV2DJIG","created_at":"2026-05-18T12:27:46Z"}],"graph_snapshots":[{"event_id":"sha256:11ac6f2a5cfe9ad3f5fcfdb9c45443f3a839ecf4015134c5d31ed3e33b2db529","target":"graph","created_at":"2026-05-18T02:56:12Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"paper":{"abstract_excerpt":"Background: Recent studies have shown a decrease in annualised relapse rates (ARRs) in placebo groups of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RMS).\n  Methods: We conducted a systematic literature search of RCTs in RMS. Data on eligibility criteria and baseline characteristics were extracted and tested for significant trends over time. A meta-regression was conducted to estimate their contribution to the decrease of trial ARRs over time.\n  Results: We identified 56 studies. Patient age at baseline (p < 0.001), mean duration of multiple sclerosis (MS) at baseline ","authors_text":"Christian R\\\"over, Richard Nicholas, Sebastian Straube, Simon M. Steinvorth, Simon Schneider, Tim Friede","cross_cats":[],"headline":"","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2013-03-12T08:31:19Z","title":"Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: systematic review and meta-regression"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1303.2803","kind":"arxiv","version":2},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:29c3b1da096e646fe93c2dd30aad4a58e9a947bef216ece16b8d9b7d8994edcf","target":"record","created_at":"2026-05-18T02:56:12Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"39ddcdb62139a31a8800153cb724186afd8c685b63d4d8f47a53c1d0e2087897","cross_cats_sorted":[],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"stat.AP","submitted_at":"2013-03-12T08:31:19Z","title_canon_sha256":"08faf0cb8263c47f89b83136986af4e8d0cd1dc6d779942a6831bb7f98664cc0"},"schema_version":"1.0","source":{"id":"1303.2803","kind":"arxiv","version":2}},"canonical_sha256":"39eba1a506a08a536dfa34b3ad59f39157bf71264a9b7232c84cb5f32209a646","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"39eba1a506a08a536dfa34b3ad59f39157bf71264a9b7232c84cb5f32209a646","first_computed_at":"2026-05-18T02:56:12.768733Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-05-18T02:56:12.768733Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"FnFZnJy4AsuXcHi0zYbLdGzT8T3MIU1iKsCbAzQUOhMegj9WbnOi9es/mdwggYYsTBYT0g/yDLFPJKHoMLpxDA==","signature_status":"signed_v1","signed_at":"2026-05-18T02:56:12.769094Z","signed_message":"canonical_sha256_bytes"},"source_id":"1303.2803","source_kind":"arxiv","source_version":2}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:29c3b1da096e646fe93c2dd30aad4a58e9a947bef216ece16b8d9b7d8994edcf","sha256:11ac6f2a5cfe9ad3f5fcfdb9c45443f3a839ecf4015134c5d31ed3e33b2db529"],"state_sha256":"556aad0be339ec3171e954f29826d3f178c6dee2768a55c37c35f387cf908535"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"YtAC4xAN1Yoxj8dIjovIjnRtf48KClrmTV0H3xmKAlRjVWTFIwCots3dUt6STBFxitzDct2LZtVqHWjN4cgEDQ==","signed_message":"bundle_sha256_bytes","signed_at":"2026-05-25T11:59:04.377891Z","bundle_sha256":"47f20113044bb56e7890bbdb82182575d709a8ea156044d5cf06eceac43cc87b"}}